Retatrutide's phase 3 story has been told almost entirely through company press releases and conference slides. That changed with the publication of TRANSCEND-T2D-1 in The Lancet — the first randomised phase 3 retatrutide trial to clear independent peer review. The surprise for anyone following the weight-loss headlines: it isn't the obesity trial. It's a type 2 diabetes study.

That distinction matters more than it sounds. Peer review is where trial numbers get pressure-tested by people who don't work for the sponsor, and until now every big retatrutide phase 3 figure in circulation — including the 28.3% average weight loss at 12mg in TRIUMPH-1 — has come from Eli Lilly topline announcements and meeting presentations rather than a published, refereed paper.

Retatrutide Phase 3: What TRANSCEND-T2D-1 Actually Tested

TRANSCEND-T2D-1 was a 40-week, double-blind, randomised, placebo-controlled trial run at 48 sites across the United States, Mexico and India. It randomised 537 adults with type 2 diabetes whose glucose was inadequately controlled on diet and exercise alone — so retatrutide was tested as monotherapy, not as an add-on to metformin or anything else.

Participants were assigned 1:1:1:1 to retatrutide 4mg, 9mg, 12mg or placebo, starting at 2mg with four-weekly escalation. Mean baseline HbA1c was 7.9%, mean BMI was around 35.8, and mean diabetes duration was roughly 2.5 years. That's a relatively early-disease, high-BMI population — worth remembering when comparing these numbers to trials in longer-standing diabetes.

The glycaemic numbers

HbA1c fell by 1.69, 1.86 and 1.94 percentage points on 4mg, 9mg and 12mg respectively, against 0.81 points with placebo. The estimated treatment difference versus placebo at 12mg was about −1.12 percentage points.

The proportion-based figures are arguably the more clinically legible ones: between 82% and 89% of retatrutide-treated participants got below the 7.0% HbA1c target, and 75% to 83% reached 6.5% or lower.

The weight numbers

Weight loss reporting for this trial varies slightly depending on which analysis is quoted — Lilly's topline described a reduction of up to 16.8% (about 36.6 lb) at 40 weeks, while other reporting of the same trial describes roughly 11.5% to 15.3% across doses versus about 2.6% on placebo. Either way, the curve had not flattened by the end of the 40-week treatment period.

Cardiometabolic markers also moved: non-HDL cholesterol, triglycerides and systolic blood pressure all improved. Those are secondary findings, not outcome data — this trial was not designed or powered to show reductions in heart attacks or strokes.

Why This Isn't the Same as the TRIUMPH Weight-Loss Data

It's easy to blur the two programmes together, so it's worth separating them. TRANSCEND-T2D is the type 2 diabetes programme. TRIUMPH is the obesity programme — and TRIUMPH-1, TRIUMPH-2 and TRIUMPH-3 are what Lilly has said will form the basis of its broad obesity marketing application to the FDA, with a Biologics License Application planned for the first quarter of 2027 once the chemistry, manufacturing and controls package is complete.

Two more reasons the numbers aren't interchangeable: TRANSCEND-T2D-1 ran 40 weeks, while TRIUMPH-1 ran 80 weeks with a blinded extension out to 104 weeks. And weight loss is consistently smaller in people with type 2 diabetes across this entire drug class — TRIUMPH-2, in obesity plus diabetes, reported up to 20.8% at 80 weeks against up to 28.3% in the non-diabetes TRIUMPH-1 population. You can read more about how the trial families fit together on our clinical trials page.

The Safety Detail Worth Reading Twice

The gastrointestinal profile was what you'd expect from an incretin drug: nausea, diarrhoea and vomiting concentrated during dose escalation. Discontinuations due to adverse events ran 2.2% to 5.1% across the retatrutide arms versus 0% on placebo.

The more distinctive finding is dysesthesia — abnormal or unpleasant skin sensation. It was reported in 4.5%, 2.3% and 4.4% of the 4mg, 9mg and 12mg arms respectively, and in 0.0% of the placebo group. Reported events were generally mild and the majority resolved while participants stayed on treatment. It's a small absolute number, but a clean zero in placebo makes it a signal rather than background noise, and it's one to watch as the larger datasets publish. More on the known tolerability picture in our safety overview.

What Peer Review Does and Doesn't Settle

Publication in a major journal means the methods, statistics and safety tables were examined by independent reviewers — a meaningfully higher bar than a press release. What it does not do is resolve the questions that still sit over retatrutide: durability beyond two years, cardiovascular outcomes, how it performs head-to-head against tirzepatide (TRIUMPH-5 is the trial designed to answer that, and it has not reported), and how the triple-agonist mechanism behaves outside a trial population. For a plain-English explanation of the GLP-1 + GIP + glucagon design, see what is retatrutide.

For Australian readers, one practical note: this trial ran at sites in the US, Mexico and India, and nothing in it changes retatrutide's Australian status. It remains investigational and not TGA-approved, and Lilly's stated regulatory plan begins with a US filing from 2027 — details on our Australia page.

Want the next readout the day it lands? Join the free updates list.

FAQ

Has retatrutide phase 3 data been peer reviewed?

Partly. TRANSCEND-T2D-1, a phase 3 type 2 diabetes trial, has been published in The Lancet. The headline obesity results from the TRIUMPH programme, including TRIUMPH-1's 28.3% average weight loss at 12mg, have so far been released as company topline announcements and conference presentations.

What is TRANSCEND-T2D-1?

It's a 40-week, double-blind, randomised, placebo-controlled phase 3 trial of retatrutide 4mg, 9mg and 12mg as monotherapy in 537 adults with type 2 diabetes inadequately controlled on diet and exercise, run at 48 sites in the US, Mexico and India.

How much weight did people lose in the retatrutide diabetes trial?

Reported figures range from roughly 11.5% to 15.3% across doses versus about 2.6% on placebo, with Lilly's topline describing up to 16.8% (about 36.6 lb) at 40 weeks. Weight loss had not plateaued by the end of treatment.

Is retatrutide approved for type 2 diabetes anywhere?

No. Retatrutide is investigational and has no marketing authorisation in the US, EU, UK or Australia. Lilly has said it plans to submit a Biologics License Application to the FDA in the first quarter of 2027, based on the TRIUMPH obesity trials.

Sources

This article is general information only and is not medical advice. Retatrutide is an investigational medicine and is not approved by the TGA or any other regulator. Speak to a qualified Australian health professional about your own circumstances. retatrutide.net.au is an independent information site and is not affiliated with, endorsed by or sponsored by Eli Lilly and Company.